Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products

Sponsor
Imperial Brands PLC (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06093659
Collaborator
(none)
25
1
5
16.9
1.5

Study Details

Study Description

Brief Summary

This is a randomised, cross-over, open-label, confinement study conducted in 25 adult male or female smokers of combustible cigarettes (CCs). The study investigates combustible cigarettes, heated tobacco products (HTPs), and Heated Herbal Products (HHPs), with endpoints including pharmacokinetic evaluation, and subjective effects.

Subjects will perform a Screening Visit and one Study Visit, including a 6-day confinement period.

Condition or Disease Intervention/Treatment Phase
  • Other: Pulze device with heated tobacco sticks (Product A)
  • Other: Pulze device with heated tobacco sticks (Product B)
  • Other: Pulze device with nicotine-infused heated herbal sticks (Product C)
  • Other: Pulze device with nicotine-infused heated herbal sticks (Product D)
  • Other: Conventional Cigarette (Product E)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Randomised, Cross-Over, Nicotine Pharmacokinetic and Pharmacodynamic Study of Heated Tobacco and Heated Herbal Products Compared With Combustible Cigarettes
Actual Study Start Date :
Jul 7, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Product use sequence ABECD

Subjects use Product A on Day 1, Product B on Day 2, Product E on Day 3 and Product C on Day 4 and Product D on Day 5.

Other: Pulze device with heated tobacco sticks (Product A)
Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with heated tobacco sticks (Product B)
Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product C)
Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product D)
Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Conventional Cigarette (Product E)
Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Experimental: Product use sequence BCADE

Subjects use Product B on Day 1, Product C on Day 2, Product A on Day 3 and Product D on Day 4 and Product E on Day 5.

Other: Pulze device with heated tobacco sticks (Product A)
Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with heated tobacco sticks (Product B)
Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product C)
Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product D)
Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Conventional Cigarette (Product E)
Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Experimental: Product use sequence CDBEA

Subjects use Product C on Day 1, Product D on Day 2, Product B on Day 3 and Product E on Day 4 and Product A on Day 5.

Other: Pulze device with heated tobacco sticks (Product A)
Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with heated tobacco sticks (Product B)
Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product C)
Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product D)
Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Conventional Cigarette (Product E)
Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Experimental: Product use sequence DECAB

Subjects use Product D on Day 1, Product E on Day 2, Product C on Day 3 and Product A on Day 4 and Product B on Day 5.

Other: Pulze device with heated tobacco sticks (Product A)
Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with heated tobacco sticks (Product B)
Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product C)
Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product D)
Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Conventional Cigarette (Product E)
Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Experimental: Product use sequence EADBC

Subjects use Product E on Day 1, Product A on Day 2, Product D on Day 3 and Product B on Day 4 and Product C on Day 5.

Other: Pulze device with heated tobacco sticks (Product A)
Product A, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with heated tobacco sticks (Product B)
Product B, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product C)
Product C, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Pulze device with nicotine-infused heated herbal sticks (Product D)
Product D, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Other: Conventional Cigarette (Product E)
Subject's own brand combustible cigarette used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration), followed by an ad-libitum, 4-hour product use session on the same day.

Outcome Measures

Primary Outcome Measures

  1. Nicotine Cmax [5 minutes pre-study product use and at 2, 4, 6, 8, 10, 15, 30, 45, 60, 120, and 240 minutes following the start of study product use]

    Maximum measured plasma nicotine concentration, for the controlled product use session

  2. Nicotine AUCt [5 minutes pre-study product use and at 2, 4, 6, 8, 10, 15, 30, 45, 60, 120, and 240 minutes following the start of study product use]

    The area under the concentration time curve for nicotine, from time 0 to the last observed non-zero concentration, for the controlled product use session

Secondary Outcome Measures

  1. Smoking urges Emax [10 minutes prior to the start of the product use session, and at 4, 8, 15, 45, 60, 120 and 240 following the start of study product use minutes]

    The maximum change from baseline Visual Analog Scale (VAS) score (VASpre-use - VASpost-use). Subjects answer the question "Right now, how much would you like to smoke a cigarette?" on a VAS: from Not at all on the left (0%) to A great deal on the right (100%), for the controlled product use session.

  2. Puff count [2 hours]

    Number of puffs taken during 2 hours of the 4-hour ad-libitum product use session

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Reports smoking an average of at least 10 manufactured combustible (menthol or non-menthol) cigarettes per day for at least 12 months prior to Screening

  • Has a positive urine cotinine (>500 ng/mL) at Screening

  • Has an exhaled carbon monoxide >10 ppm at Screening

  • Female subjects of childbearing potential must use contraception

  • Male subjects must use contraception

Exclusion Criteria:
  • Has a history or presence of clinically significant disease or condition that, in the opinion of the Investigator, would jeopardise the safety of the subject or impact the validity of the study results.

  • Has a positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at Screening

  • Has a body mass index (BMI) > 30.0 kg/m2 or < 18.0 kg/m2 at Screening

  • Has a fever (>38.05°C) at Screening or check-in

  • Has a history or presence of drug or alcohol abuse within 24 months of Check-in

  • Pregnant or lactating females

  • Has used any prescription smoking cessation treatments within 3 months prior to Check-in Is planning to quit smoking during the study or within the next 3 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Celerion Belfast United Kingdom

Sponsors and Collaborators

  • Imperial Brands PLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Imperial Brands PLC
ClinicalTrials.gov Identifier:
NCT06093659
Other Study ID Numbers:
  • NER 01/005
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 23, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 23, 2023